Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH Funding Boosts New Alzheimer’s Research

Published: Wednesday, September 18, 2013
Last Updated: Wednesday, September 18, 2013
Bookmark and Share
$45 million has been awarded to test early interventions and explore new approaches.

Researchers will test promising drugs aimed at preventing Alzheimer’s and identify and validate biological targets for novel therapies, with approximately $45 million in new funding from the National Institutes of Health. The initiative will support innovative new studies as part of an intensified national effort to find effective interventions for this devastating degenerative brain disease. 

The studies are among the first to be developed with direction from the 2012 NIH Alzheimer’s Disease Research Summit: Path to Treatment and Prevention and reflect research goals in the National Plan to Address Alzheimer’s Disease. Of the funding, $40 million is from an allocation from the Office of the NIH Director, Dr. Francis Collins, with additional funding from the National Institute on Aging (NIA), the lead Institute within NIH for Alzheimer’s research. 

“As many as 5 million Americans face the challenge of Alzheimer’s disease, which robs them of their memories, their independence, and ultimately, their lives,” Dr. Collins said. “We are determined, even in a time of constrained fiscal resources, to capitalize on exciting scientific opportunities to advance understanding of Alzheimer’s biology and find effective therapies as quickly as possible.” 

The clinical trials investigate possible ways to stop the progression of the disease. The translational research study awards are focused on identifying, characterizing and validating novel therapeutic targets.

“We know that Alzheimer’s-related brain changes take place years, even decades, before symptoms appear. That really may be the optimal window for drugs that delay progression or prevent the disease altogether,” said NIA Director Dr. Richard Hodes. “The clinical trials getting under way with these funds will test treatments in symptom-free volunteers at risk for the disease, or those in the very earliest stages — where we hope we can make the biggest difference.” 

Basic and genetic studies of the disease — from the abnormal proteins involved, to genetic influences, to inflammation and other Alzheimer’s - related brain changes—have advanced our knowledge. This has given us new insights into the biological underpinnings of this extremely complex disorder, Dr. Hodes said. 

Today’s awards support the following clinical trials. (Individual investigators can be contacted about when these studies will recruit participants.):

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Trial — Dr. Randall Bateman, Washington University, St. Louis, and co-investigators. $1.5 million in fiscal 2013, with the potential for $6 million over four years

The trial is testing new anti-amyloid-beta drug treatments in volunteers who have an inherited form of Alzheimer’s disease. While early-onset Alzheimer’s is rare, the knowledge gained from this study will be highly relevant to both early-and late-onset forms of the disease. This rare form can occur in people as early as their 30s. Amyloid plaques in the brain are a hallmark of Alzheimer’s and are thought to interfere with communication among brain cells, and anti-amyloid-beta therapies attempt to treat that process. Dr. Bateman will lead a team recruiting volunteers free of symptoms or in the earliest stages of the disorder.

The four-year trial, a multi-site international effort, will test three anti-amyloid-beta interventions: gantenerumab, solanezumab and a third, as yet undetermined, drug. This trial is also supported by the Alzheimer's Association® and the following companies: Roche, Lilly, Avid Radiopharmaceuticals and CogState. (NIA support: AG042791-01A1)

The Alzheimer's Prevention Initiative APOE4 Trial — Drs. Eric Reiman and Pierre Tariot, Banner Alzheimer’s Institute, Phoenix, and co-investigators. Fully funded in fiscal 2013 at $33.2 million 

This five-year prevention trial proposes to test an anti-amyloid drug in cognitively normal older volunteers who are at increased risk of developing late-onset Alzheimer’s because they inherited two copies of the APOE4 allele, the best known genetic risk for late-onset disease. The treatment, which has not yet been selected, will be tested in this randomized, controlled clinical trial at multiple sites. Participants will be assessed through cognitive tests, brain imaging and cerebrospinal fluid measurements to evaluate whether the drug impacts amyloid, other biological measurements and the memory and thinking problems related to the disease. The study will test the role of amyloid in the development of Alzheimer’s and will, through imaging and biomarker techniques, help identify faster ways to evaluate other promising prevention therapies in the future. It is anticipated that the study will also be supported with private funding. (NIA support: AG 046150-01)

Allopregnanolone Regenerative Therapeutic for MCI/Alzheimer’s: Dose Finding Phase 1 — Drs. Roberta Brinton and Lon Schneider, University of Southern California, Los Angeles. Fully funded in fiscal 2013 at $2.4 million

This early-phase clinical trial will evaluate over 12 weeks the safety and tolerability of increasing doses of allopregnanolone, a natural brain steroid, in treating mild cognitive impairment and Alzheimer’s disease. The drug has been shown to promote the generation of new brain cells, reduce amyloid levels, and restore cognitive function in pre-clinical animal testing. NIA has supported Dr. Brinton’s research over many years, including basic science grants to understand allopregnanolone’s mechanism of action in the brain, a drug development grant which included development of optimal dose and formulation, and support for pre-clinical toxicology studies. This support helped bring Dr. Brinton and colleagues to the stage of being able to go into a human Phase I trial. (NIA support: AG 046148-01) Studies focused on the identification and validation of novel therapeutic targets for Alzheimer’s disease include: 

Pathway Discovery, Validation and Compound Identification for Alzheimer’s Disease — Drs. Philip De Jager, of the Brigham and Women's Hospital, Broad Institute, Harvard University, Boston, and David Bennett, of Rush University Medical Center, Chicago. $1.7 million in fiscal 2013, with the potential of $7.9 million over five years

The study will discover, characterize and validate complex molecular networks and candidate genes that influence susceptibility to cognitive decline and Alzheimer’s disease. Using cutting-edge computational methods, this multi-disciplinary team will analyze rich clinical, pathological, genomic and other large-scale molecular data collected from over 1,000 volunteers from the Religious Order Study and the Rush Memory and Aging Project. 

Through a systems biology approach looking at biological interactions involved in the disease, the project ultimately seeks to identify compounds that normalize the activity of dysfunctional nodes in molecular networks and to identify drugs for several novel therapeutic targets. To accelerate the testing of promising therapies for future clinical trials, the researchers will focus on drugs that have already undergone Phase I testing in humans. (NIA support: AG 046152)

Integrative Biology Approach to Complexity of Alzheimer’s Disease — Dr. Eric Schadt of Icahn School of Medicine at Mount Sinai, New York City, and a team of investigators. $1.6 million in fiscal 2013, with the potential of $8.2 million over five years

This study will apply innovative analytical methods to large-scale molecular, cellular and clinical data from Alzheimer’s patients to construct biological network models and gain new insights into the complex mechanisms of the disease. Several cellular and animal models will be used to validate the actions of individual genes, as well as entire molecular networks predicted to drive the disease. The team will also employ a computational approach to test whether any existing drugs currently used for other conditions are capable of modulating the Alzheimer’s networks and can, therefore, be repurposed for Alzheimer’s treatment or prevention. (NIA support: AG 046170-01)

A Systems Approach to Targeting Innate Immunity in Alzheimer’s — Dr. Todd Golde, University of Florida, Gainesville, and colleagues. $1.6 million in fiscal 2013, with the potential of $7.7 million over five years

This study builds on the genetic and pathological evidence that the innate immune system, which provides immediate defense against infection, and brain inflammation have a significant role in Alzheimer’s disease. To identify and characterize novel therapeutic targets within the innate immune system, this study will use a systems biology approach to integrate genomic, gene expression, and pathological data from Alzheimer’s patients and Alzheimer’s mouse models and analyze them in novel ways. The team will test in animal models of the disease the validity and therapeutic potential of the key factors predicted by the analysis. This has the potential to speed the discovery and testing of Alzheimer’s disease prevention and treatment therapies by targeting the immune system. (NIA support: AG 046139-01).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exploring the Genome of the River Blindness Parasite
Researchers have decoded the genome of the parasite that causes the skin and eye infection known as river blindness.
Wednesday, December 07, 2016
Gene-Editing Improves Vision in Blind Rats
Scientists developed a targeted gene-replacement technique that can modify genes in both dividing and non-dividing cells in living animals.
Wednesday, December 07, 2016
Uncovering Cerebral Malaria’s Deadly Agents
NIH scientists film inside mouse brains to uncover biology behind the disease.
Wednesday, December 07, 2016
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Wednesday, November 30, 2016
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Wednesday, November 30, 2016
Antibody Protects Mice from Zika Infection
Researchers develop human-derived antibody protected pregnant mice and their developing fetuses from Zika infection.
Wednesday, November 23, 2016
Food Additives Promote Inflammation, Colon Cancer
Dietary emulsifiers promoted colon cancer in a mouse model by altering gut microbes and increasing gut inflammation.
Wednesday, November 23, 2016
Protein-Folding Gene Helps Heal Wounds
Researchers identified a protein that dramatically accelerates wound healing in animal models.
Wednesday, November 23, 2016
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Monday, November 21, 2016
Big Data for Infectious Disease Surveillance
NIH-led effort examines use of big data from health records and other digital sources for uses in infectious disease surveillance.
Tuesday, November 15, 2016
Potential Therapies Against Drug-Resistant Bacteria Identified
Researchers create new identification method for drug and drug combinations that may combat resistant infections.
Thursday, November 10, 2016
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Tuesday, November 08, 2016
Genetic Markers Predict Malaria Treatment Failure
By comparing 297 parasite genomes to a reference malaria parasite genome, researchers have identified two genetic markers that are strongly associated with the parasites’ ability to resist piperaquine.
Monday, November 07, 2016
Cannabinoid Receptor Structure Revealed
Scientists provided a detailed view of the primary molecule through which cannabinoids exert their effects on the brain. The findings might help guide the design of more targeted medicines with fewer side effects.
Wednesday, November 02, 2016
NIH Researchers Unveil New Wound-Healing Role for Protein-Folding Gene in Mice
The study found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model.
Friday, October 28, 2016
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Unique Visual Stimulation May Be New Treatment for Alzheimer’s
Noninvasive technique reduces beta amyloid plaques in mouse models of Alzheimer’s disease.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!